Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CATP LNP + SamRNA-IL12
- Development stage
- Preclinical
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Injection
01
Overview
CATP LNP + SamRNA-IL12 is an experimental cancer immunotherapy that utilizes Cascade Amplification of Therapeutic Payloads (CATP) technology. This approach employs lipid nanoparticles (LNPs) to co-deliver self-amplifying mRNA (SamRNA) encoding the immunostimulatory cytokine interleukin-12 (IL-12) along with modified mRNA encoding alphavirus capsid and envelope proteins. The therapy functions through a dual-amplification mechanism: the SamRNA replicates within the initially transfected cells to drive high levels of IL-12 expression, while the structural proteins package the SamRNA into defective viral particles (DVPs). These DVPs are then released to transduce neighboring cells, effectively propagating the therapeutic payload throughout the tumor microenvironment. Preclinical studies have demonstrated efficacy in models of B16F10 melanoma and pancreatic ductal adenocarcinoma by enhancing anti-tumor immune responses.
- Other names
- CATP LNPSamRNA-IL12SamRNA-IL-12SamRNA-IL 12
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on CATP LNP + SamRNA-IL12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CATP LNP + SamRNA-IL12.